Thrombopoietin As Biomarker and Mediator of Cardiovascular Damage in Critical Diseases

Overview

Journal Mediators Inflamm

Publisher Wiley

Specialties Biochemistry
Pathology

Date 2012 May 12

PMID 22577249

Citations 17

Authors

Enrico Lupia

Alberto Goffi

Ornella Bosco

Giuseppe Montrucchio

Affiliations

Soon will be listed here.

Abstract

Thrombopoietin (TPO) is a humoral growth factor originally identified for its ability to stimulate the proliferation and differentiation of megakaryocytes. In addition to its actions on thrombopoiesis, TPO directly modulates the homeostatic potential of mature platelets by influencing their response to several stimuli. In particular, TPO does not induce platelet aggregation per se but is able to enhance platelet aggregation in response to different agonists ("priming effect"). Our research group was actively involved, in the last years, in characterizing the effects of TPO in several human critical diseases. In particular, we found that TPO enhances platelet activation and monocyte-platelet interaction in patients with unstable angina, chronic cigarette smokers, and patients with burn injury and burn injury complicated with sepsis. Moreover, we showed that TPO negatively modulates myocardial contractility by stimulating its receptor c-Mpl on cardiomyocytes and the subsequent production of NO, and it mediates the cardiodepressant activity exerted in vitro by serum of septic shock patients by cooperating with TNF-α and IL-1β. This paper will summarize the most recent results obtained by our research group on the pathogenic role of elevated TPO levels in these diseases and discuss them together with other recently published important studies on this topic.

Citing Articles

Pericardial Fluid of Patients With Coronary Artery Disease Can Drive Fibrosis Via TGF-Beta Pathway.

Hassanabad A, Belke D, Gordon P, Teng G, Dundas J, Zarzycki A JACC Basic Transl Sci. 2024; 9(11):1329-1344.

PMID: 39619141 PMC: 11604402. DOI: 10.1016/j.jacbts.2024.06.007.

Correlation between thrombopoietin and inflammatory factors, platelet indices, and thrombosis in patients with sepsis: A retrospective study.

Xu W, Mo L, Shi M, Rao H, Zhan X, Yang M World J Clin Cases. 2022; 10(13):4072-4083.

PMID: 35665097 PMC: 9131241. DOI: 10.12998/wjcc.v10.i13.4072.

Thrombopoietin Contributes to Enhanced Platelet Activation in Patients with Type 1 Diabetes Mellitus.

Bosco O, Vizio B, Gruden G, Schiavello M, Lorenzati B, Cavallo-Perin P Int J Mol Sci. 2021; 22(13).

PMID: 34210000 PMC: 8269076. DOI: 10.3390/ijms22137032.

Platelets as a prognostic marker for sepsis: A cohort study from the MIMIC-III database.

Zhao L, Zhao L, Wang Y, Yang F, Chen Z, Yu Q Medicine (Baltimore). 2020; 99(45):e23151.

PMID: 33157998 PMC: 7647525. DOI: 10.1097/MD.0000000000023151.

Protein thiol oxidation in the rat lung following e-cigarette exposure.

Wang J, Zhang T, Johnston C, Kim S, Gaffrey M, Chalupa D Redox Biol. 2020; 37:101758.

PMID: 33080441 PMC: 7575796. DOI: 10.1016/j.redox.2020.101758.

References

Silverman H, Penaranda R, Orens J, Lee N . Impaired beta-adrenergic receptor stimulation of cyclic adenosine monophosphate in human septic shock: association with myocardial hyporesponsiveness to catecholamines. Crit Care Med. 1993; 21(1):31-9. DOI: 10.1097/00003246-199301000-00010. View

Oygur N, Tunga M, Mumcu Y, Yesilipek A, Gura A, Coskun M . Thrombopoietin levels of thrombocytopenic term and preterm newborns with infection. Am J Perinatol. 2001; 18(5):279-86. DOI: 10.1055/s-2001-16990. View

van Os E, Wu Y, Pouwels J, IJsseldijk M, Sixma J, Akkerman J . Thrombopoietin increases platelet adhesion under flow and decreases rolling. Br J Haematol. 2003; 121(3):482-90. DOI: 10.1046/j.1365-2141.2003.04292.x. View

Post H, Schulz R, Gres P, Heusch G . No involvement of nitric oxide in the limitation of beta-adrenergic inotropic responsiveness during ischemia. Am J Physiol Heart Circ Physiol. 2001; 281(6):H2392-7. DOI: 10.1152/ajpheart.2001.281.6.H2392. View

Zakynthinos S, Papanikolaou S, Theodoridis T, Zakynthinos E, Christopoulou-Kokkinou V, Katsaris G . Sepsis severity is the major determinant of circulating thrombopoietin levels in septic patients. Crit Care Med. 2004; 32(4):1004-10. DOI: 10.1097/01.ccm.0000121433.61546.a0. View

Kumar A, Thota V, Dee L, Olson J, Uretz E, Parrillo J . Tumor necrosis factor alpha and interleukin 1beta are responsible for in vitro myocardial cell depression induced by human septic shock serum. J Exp Med. 1996; 183(3):949-58. PMC: 2192364. DOI: 10.1084/jem.183.3.949. View

Senaran H, Ileri M, Altinbas A, Kosar A, Yetkin E, Ozturk M . Thrombopoietin and mean platelet volume in coronary artery disease. Clin Cardiol. 2001; 24(5):405-8. PMC: 6655056. DOI: 10.1002/clc.4960240511. View

Terada Y, Hato F, Sakamoto C, Hasegawa T, Suzuki K, Nakamae H . Thrombopoietin stimulates ex vivo expansion of mature neutrophils in the early stages of differentiation. Ann Hematol. 2003; 82(11):671-6. DOI: 10.1007/s00277-003-0729-7. View

Thielmann M, Dorge H, Martin C, Belosjorow S, Schwanke U, van de Sand A . Myocardial dysfunction with coronary microembolization: signal transduction through a sequence of nitric oxide, tumor necrosis factor-alpha, and sphingosine. Circ Res. 2002; 90(7):807-13. DOI: 10.1161/01.res.0000014451.75415.36. View

10.

Colarizi P, Fiorucci P, Caradonna A, Ficuccilli F, Mancuso M, Papoff P . Circulating thrombopoietin levels in neonates with infection. Acta Paediatr. 1999; 88(3):332-7. DOI: 10.1080/08035259950170132. View

11.

Chan K, Xiang P, Zhou L, Li K, Ng P, Wang C . Thrombopoietin protects against doxorubicin-induced cardiomyopathy, improves cardiac function, and reversely alters specific signalling networks. Eur J Heart Fail. 2011; 13(4):366-76. DOI: 10.1093/eurjhf/hfr001. View

12.

Chakhtoura E, Shamoon F, HAFT J, Obiedzinski G, Cohen A, Watson R . Comparison of platelet activation in unstable and stable angina pectoris and correlation with coronary angiographic findings. Am J Cardiol. 2000; 86(8):835-9. DOI: 10.1016/s0002-9149(00)01102-4. View

13.

Mendall M, Patel P, Asante M, Ballam L, Morris J, Strachan D . Relation of serum cytokine concentrations to cardiovascular risk factors and coronary heart disease. Heart. 1997; 78(3):273-7. PMC: 484930. DOI: 10.1136/hrt.78.3.273. View

14.

Fiedel B, Gewurz H . Effects of C-reactive protein on platelet function. I. Inhibition of platelet aggregation and release reactions. J Immunol. 1976; 116(5):1289-94. View

15.

Kaushansky K, Lin N, Grossmann A, Humes J, Sprugel K, Broudy V . Thrombopoietin expands erythroid, granulocyte-macrophage, and megakaryocytic progenitor cells in normal and myelosuppressed mice. Exp Hematol. 1996; 24(2):265-9. View

16.

Gurney A, de Sauvage F, Moore M . Thrombocytopenia in c-mpl-deficient mice. Science. 1994; 265(5177):1445-7. DOI: 10.1126/science.8073287. View

17.

Sigurjonsson O, Gudmundsson K, Haraldsdottir V, Rafnar T, Agnarsson B, Gudmundsson S . Flt3/Flk-2 ligand in combination with thrombopoietin decreases apoptosis in megakaryocyte development. Stem Cells Dev. 2004; 13(2):183-91. DOI: 10.1089/154732804323046783. View

18.

Merx M, Weber C . Sepsis and the heart. Circulation. 2007; 116(7):793-802. DOI: 10.1161/CIRCULATIONAHA.106.678359. View

19.

Lange R, Hillis L . Antiplatelet therapy for ischemic heart disease. N Engl J Med. 2004; 350(3):277-80. DOI: 10.1056/NEJMe038191. View

20.

Hescheler J, Meyer R, Plant S, Krautwurst D, Rosenthal W, Schultz G . Morphological, biochemical, and electrophysiological characterization of a clonal cell (H9c2) line from rat heart. Circ Res. 1991; 69(6):1476-86. DOI: 10.1161/01.res.69.6.1476. View